What is General Proximity?
General Proximity is pioneering the first generalized, mechanism-agnostic proximity discovery engine. The company's core innovation lies in understanding and leveraging the intricate molecular machines, or effector proteins, that govern biological processes. These proteins, including chaperone, adaptor, and trafficking proteins, along with post-translational modification readers, writers, and erasers, are fundamental to all aspects of biology. By developing a sophisticated engine for proximity discovery, General Proximity aims to unlock new avenues for research and application within the life sciences and biotechnology sectors, potentially revolutionizing how biological interactions are understood and manipulated.
How much funding has General Proximity raised?
General Proximity has raised a total of $16M across 1 funding round:
Angel/Seed
$16M
Angel/Seed (2025): $16M with participation from Y Combinator, The Rock Creek Group, and Felicis Ventures
Key Investors in General Proximity
Y Combinator
Y Combinator is a renowned startup accelerator that provides seed funding and mentorship to early-stage companies, known for its rigorous selection process and successful track record in launching innovative ventures.
The Rock Creek Group
The Rock Creek Group is a global investment firm specializing in integrating innovation into investment strategies, with a focus on sustainability and providing outsourced investment management solutions for institutional clients.
Felicis Ventures
Felicis Ventures is a venture capital firm that invests in early and growth-stage technology companies, with a particular emphasis on SaaS, AI, and fintech, often leading seed and Series A rounds.
What's next for General Proximity?
The recent major strategic investment signals a strong validation of General Proximity's technological approach and market potential. This capital infusion is expected to accelerate the company's growth trajectory, enabling further development of its proximity discovery engine and expansion into new enterprise markets. The focus will likely be on scaling operations, enhancing the platform's capabilities, and forging strategic partnerships to integrate its technology into broader biological and pharmaceutical research workflows. This funding positions General Proximity to become a key player in the advanced biotechnology and molecular discovery space.
See full General Proximity company page
